- Home
- DSM vs OLMA Comparison
DSM vs OLMA Comparison
Compare DSM & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- OLMA
- Stock Information
- Founded
- DSM 1989
- OLMA 2006
- Country
- DSM United States
- OLMA United States
- Employees
- DSM N/A
- OLMA N/A
- Industry
- DSM Investment Managers
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- OLMA Health Care
- Exchange
- DSM Nasdaq
- OLMA Nasdaq
- Market Cap
- DSM 275.8M
- OLMA 299.7M
- IPO Year
- DSM N/A
- OLMA 2020
- Fundamental
- Price
- DSM $5.67
- OLMA $4.41
- Analyst Decision
- DSM
- OLMA Strong Buy
- Analyst Count
- DSM 0
- OLMA 4
- Target Price
- DSM N/A
- OLMA $24.50
- AVG Volume (30 Days)
- DSM 161.7K
- OLMA 1.1M
- Earning Date
- DSM 01-01-0001
- OLMA 08-05-2025
- Dividend Yield
- DSM 3.97%
- OLMA N/A
- EPS Growth
- DSM N/A
- OLMA N/A
- EPS
- DSM N/A
- OLMA N/A
- Revenue
- DSM N/A
- OLMA N/A
- Revenue This Year
- DSM N/A
- OLMA N/A
- Revenue Next Year
- DSM N/A
- OLMA N/A
- P/E Ratio
- DSM N/A
- OLMA N/A
- Revenue Growth
- DSM N/A
- OLMA N/A
- 52 Week Low
- DSM $4.69
- OLMA $2.86
- 52 Week High
- DSM $6.05
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- DSM 58.99
- OLMA 48.24
- Support Level
- DSM $5.55
- OLMA $4.45
- Resistance Level
- DSM $5.68
- OLMA $4.73
- Average True Range (ATR)
- DSM 0.04
- OLMA 0.31
- MACD
- DSM 0.01
- OLMA 0.03
- Stochastic Oscillator
- DSM 93.75
- OLMA 52.75
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.